Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
2.6
2.4
Journals
JCDD
Special Issues
Implantable Cardioverter Defibrillator (ICD) in Cardiac Disease
share announcement

Implantable Cardioverter Defibrillator (ICD) in Cardiac Disease

A special issue of Journal of Cardiovascular Development and Disease (ISSN 2308-3425). This special issue belongs to the section "Electrophysiology and Cardiovascular Physiology".

Deadline for manuscript submissions: closed (15 July 2024) | Viewed by 5535

Special Issue Editor

Dr. Cristina Balla

E-Mail Website
Guest Editor
Cardiology Department, University Hospital S. Anna Ferrara, 44121 Ferrara, Italy
Interests: arrhythmias; electrophysiology; cardiac pacing; cardiogenetics; inherited cardiac disease

Special Issue Information

Dear Colleagues,

Novel medical therapies and new interventional approaches to cardiac disease have currently changed our medical approach to patients with heart disease. However, the risk of ventricular arrhythmias and sudden cardiac death (SCD) are still a key element that every physician need to face in their patients. We set up this Special Issue in order to highlight new scientific development on risk stratification and prevention of sudden cardiac death. Therefore, for this Special Issue, we would like to select papers regarding new methodologies for risk stratification of sudden cardiac death, new insights on the use of implantable Cardioverter Defibrillator (ICD) and future approaches to the prevention of SCD.

Dr. Cristina Balla
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Cardiovascular Development and Disease is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • implantable cardioverter defibrillator
  • sudden cardiac death
  • ventricular arrhythmias
  • cardiomyopathies
  • channelopathies
  • genetics
  • cardiac imaging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

9 pages, 5505 KiB  
Article
T-Wave Oversensing with Contemporary Implantable Cardioverter–Defibrillators
by Marc Strik, Sylvain Ploux, Romain Eschalier, Pierre Mondoly, Leslie Fontagne, F. Daniel Ramirez, Michel Haïssaguerre and Pierre Bordachar
J. Cardiovasc. Dev. Dis. 2023, 10(10), 430; https://doi.org/10.3390/jcdd10100430 - 17 Oct 2023
Cited by 1 | Viewed by 2780
Abstract
Background: Implantable cardioverter–defibrillators (ICDs) need to reliably detect ventricular tachycardia (VT) and ventricular fibrillation (VF) while avoiding T-wave oversensing (TWOS), which is associated with a risk of inappropriate therapies. The incidence of TWOS with endovascular ICDs appears to differ between manufacturers. Objectives: We [...] Read more.
Background: Implantable cardioverter–defibrillators (ICDs) need to reliably detect ventricular tachycardia (VT) and ventricular fibrillation (VF) while avoiding T-wave oversensing (TWOS), which is associated with a risk of inappropriate therapies. The incidence of TWOS with endovascular ICDs appears to differ between manufacturers. Objectives: We aimed to evaluate the incidence and clinical consequences of TWOS with contemporary Medtronic and Boston Scientific ICDs. Methods: Consecutive patients implanted with a recent Medtronic or Boston Scientific ICD and remotely monitored at three French centers were included. All transmitted EGMs labelled as VF, VT, non-sustained VT (NSVT), or ventricular oversensing (Medtronic) were screened for TWOS. Results: Among 7589 transmitted episodes from 674 patients with a Boston Scientific ICD, we did not identify a single case of TWOS. Among 16,790 transmitted episodes from 1733 patients with a Medtronic ICD, we identified 60 patients (3.4%) with at least one episode of TWOS. In 46 patients, TWOS was intermittent (NSVT episodes). In the remaining 14 patients, TWOS resulted in 60 sustained episodes (completed counters). No inappropriate therapies were delivered in 12 of these patients because no therapies were programmed (in monitor zones, 11 episodes) or because therapies were inhibited by the morphology discriminator (Wavelet, 19 episodes) or by the anti-TWOS algorithm (26 episodes). Two patients received inappropriate therapies due to TWOS (0.1% of patients with Medtronic ICDs). Conclusion: On review of 24,379 transmitted episodes from 2407 patients with endovascular ICDs, we found no case of TWOS with Boston Scientific devices, whereas TWOS was not uncommon with Medtronic devices. However, the risk of inappropriate therapy with Medtronic ICDs was very low (0.1%) due to the often intermittent nature of this phenomenon, the morphology discriminator, and the anti-TWOS algorithm. Full article
(This article belongs to the Special Issue Implantable Cardioverter Defibrillator (ICD) in Cardiac Disease)
►▼ Show Figures

Figure 1

Review

Jump to: Research

24 pages, 1462 KiB  
Review
Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions
by Andrew M. Leong, Ahran D. Arnold and Zachary I. Whinnett
J. Cardiovasc. Dev. Dis. 2024, 11(3), 92; https://doi.org/10.3390/jcdd11030092 - 20 Mar 2024
Cited by 1 | Viewed by 2314
Abstract
Implantable cardioverter defibrillators (ICDs) have a long history and have progressed significantly since the 1980s. They have become an essential part of the prevention of sudden cardiac death, with a proven survival benefit in selected patient groups. However, with more recent trials and [...] Read more.
Implantable cardioverter defibrillators (ICDs) have a long history and have progressed significantly since the 1980s. They have become an essential part of the prevention of sudden cardiac death, with a proven survival benefit in selected patient groups. However, with more recent trials and with the introduction of contemporary heart failure therapy, there is a renewed interest and new questions regarding the role of a primary prevention ICD, especially in patients with heart failure of non-ischaemic aetiology. This review looks at the history and evolution of ICDs, appraises the traditional evidence for ICDs and looks at issues relating to patient selection, risk stratification, competing risk, future directions and a proposed contemporary ICD decision framework. Full article
(This article belongs to the Special Issue Implantable Cardioverter Defibrillator (ICD) in Cardiac Disease)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop